Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung

Inclusion Criteria: * informed of the study and have provided written informed consent * At least 18 years of age * Histologically confirmed diagnosis of locally advanced, or metastatic squamous cell carcinoma or adenocarcinoma histological subtypes of non-small-cell lung cancer (stage IIIB or IV) * For patients with squamous cell histology: previously treated with first-line chemotherapy and has had disease progression during or after first-line therapy. * For patients with adenocarcinoma histology: previously treated with one or two lines of chemotherapy. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Life expectancy ≥ 3 months * Measurable disease by RECIST 1.1 criteria * Hematology values: blood leukocyte count ≥ 3.0 x 109/L, blood absolute neutrophil count ≥ 1.5 x 109/L, blood platelet count ≥ 100 x109/L, hemoglobin ≥ 100 g/L (transfusions are allowed) * Clinical chemistry values: plasma total bilirubin level ≤ upper limit of the "normal" range (ULN; i.e. reference), plasma AST or ALT ≤ 1.5 x ULN (≤ 5 times if liver metastases have been documented) and plasma creatinine ≤ 2.0 x ULN * 12-lead ECG with normal tracings Exclusion Criteria: * Mixed histology of squamous and non-squamous NSCLC * Ongoing infection or other major recent or ongoing disease that, according to the Investigator, poses an unacceptable risk to the patient * Known primary or secondary central nervous system malignancy. * Active or previously treated carcinomatous meningitis * Truly non-measurable disease by RECIST 1.1 criteria, such as patients with one or more of the following without any RECIST measurable disease: * Bone lesions * Ascites * Pleural or pericardial effusion * Lymphangitis cutis or pulmonis * Cystic lesions * Grade 3 or higher constipation within the past 28 days or grade 2 constipation within the past 14 days before randomization. * Active hepatitis B, active hepatitis C, or known HIV infection * Coexisting uncontrolled medical condition, including active cardiac disease (such as unstable angina, myocardial infarction within 6 months, or New York Heart Association Class III/IV congestive heart failure), and significant dementia * Hepatic impairment as indicated by abnormalities of transaminases (AST and/or ALT \> 1.5 × ULN or AST and/or ALT \> 5 times ULN if liver metastases have been documented) and/or increased alkaline phosphatase (\> 2.5 × ULN) considered as a result of hepatic impairment (and not from bone disease) * History of cancer that has required treatment or been active within the past 5 years, other than NSCLC, basal cell carcinoma, or cervical carcinoma in situ * Major surgical procedure within 4 weeks prior to randomization * More than one prior anti-tumor systemic therapy for advanced squamous cell NSCLC, and more than two prior lines of chemotherapy for advanced adenocarcinoma NSCLC * Previous use of docetaxel in any line of therapy * Women of child bearing potential (WOCBP) who do not consent to using acceptable methods of contraception * Women who are breast-feeding or have a positive pregnancy test at screening * Current participation in any other investigational clinical trial or any administration of an investigational agent within 4 weeks of study drug administration * ECOG performance status \> 2 * Life expectancy \< 3 months * Known or suspected hypersensitivity to AXL1717 or docetaxel or to drugs formulated with polysorbate 80 * Lack of suitability for participation in the trial, for any reason, as judged by the Investigator